Reata initiates Phase II/III trial of bard to treat Alport Syndrome-caused CDK

US-based clinical-stage biopharmaceutical company Reata Pharmaceuticals has initiated patient screening in a Phase II/III trial of bardoxolone methyl (bard) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news